Maise Al Bakir

Cellular therapy consultant | Oncologist | Bioinformatician @uclh @uclcancer @TheCrick

[Maise Al Bakir @drmaiseb]

Many years in the making! Our work on metastasis in non-small cell lung cancer is out now @Nature. Very grateful to the generous patients who have taken part in #TRACERx and our funders who made this work possible.

[Charles Swanton @CharlesSwanton]

Excited to share our recent @SwantonLab @NickyMcGranahan & @MariamJHanjani lab work on the genomic evolution of non-small cell lung cancer metastases in #TRACERx, out @Nature

https://t.co/bmV9Q0cySW

A quick thread [1/13]

[Dr. Minoo Battiwalla @DrBattiwalla]

https://t.co/lrEAcQ9WSN

[Ben Solomon @bensolomon1]

Thank you @JAMA_current for highlighting the issue of lung cancer in people who have never smoked. Podcast with JAMA deputy editor Dr Kristin Walter discussing the article available online.

[Drew Moghanaki @DrewMoghanaki]

More than doubled! 🚀

[AttardLab @AttardLab]

Excited to share our study Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancer @EmilyGrist1 @marina_parry @MRCCTU @uclcancer @ProstateUK @PCFnews @Prof_Nick_James @LotanLab @Decipher_VCYT @ChrisSweens1 https://t.co/0m3J71ThrZ

[Claire Roddie @drclaireroddie]

⁦@FreddieVonberg⁩ does an excellent job of highlighting risk factors for prolonged ICANS in CART patients at the 2025 BNOS conference ⁦@BNOSofficial⁩ ⁦@uclcancer⁩ ⁦@uclh⁩ ⁦

[Mike Northend @drmikenorthend]

Great opportunity to work with myself, @drclaireroddie @maeveannoreilly @paulmaciocia and @drmaiseb in our UCLH cellular therapy team go gain experience of delivering standard of care CAR T and trials in solid onc and AID. https://t.co/CT3UcYOCee

[Maise Al Bakir @drmaiseb]

CAR-T Fellow post available @uclh. Application deadline 04/06/2025. Working with the fabulous @drclaireroddie @maeveannoreilly @paulmaciocia @drmikenorthend

https://t.co/vphnzKGqxy

[Mike Northend @drmikenorthend]

https://t.co/YDM6I3CmDN

Happy to share 15 year follow-up of our study of early rituximab vs watchful waiting for advanced stage, asymptomatic, low tumour burden FL. Substantial delay in TTNT highlights the value of early R for pts seeking to defer/avoid chemo. #lymsm #lymphoma

[UCLH @uclh]

Newly reported updated results of a study from UCLH and UCL highlights the powerful benefits of a targeted immune therapy for a type of slow-growing blood cancer.

Find out more: https://t.co/baDWGv4xY1

#Lymphoma

[Claire Roddie @drclaireroddie]

CD19 CAR-T is safe and effective for intra-cardiac NHL. Key to this is multidisciplinary care with cardio-oncology colleagues. ⁦Nice piece led by Dan Chen, ⁦@arjunkg⁩ @kathleencheok⁩ ⁦@maeveannoreilly⁩ ⁦@uclh⁩ ⁦@uclcancer⁩ https://t.co/IElIrDrId9

[Cancer Cell @Cancer_Cell]

A pan-cancer single-cell RNA-seq atlas of intratumoral B cells https://t.co/1v3v77GYvi

[Alex Rampotas @ARampotas]

Very pleased to see our work with J Richter, D Isenberg and @drclaireroddie published in @BMTjournal

https://t.co/CYrjdn9YWk

1/CAR-T cell therapy, is making strides in treating autoimmune diseases and may be the future of treating such conditions
Let’s dive in

[QingliGuo @QingliGuo]

Thrilled to share our discovery of novel long-deletion #signatures—powerful markers for tracking #MMRd #CancerEvolution, even in low-pass (~0.1X) FFPE samples with low tumour content, using our tool #MILO. Check out our preprint for the full story https://t.co/IYOpPbqVsU (1/8)

[Alex Frankell @AFrankell]

Yet more evidence that somatic copy number alterations define the malignant transition in many carcinomas - this time in CRC from IBD. Love to know the underlying biology!

[Trevor Graham @trevoragraham]

We found that measurement (by lpWGS) of aneuploidy in LGD (burden & specific genetic alterations) very strongly predicts bowel cancer risk: >90% accurate over 5 years. We think the test is good enough (& cheap & easy enough) to be evaluated for clinical use in years ahead. [2/3]

[Trevor Graham @trevoragraham]

Inflammatory bowel disease (#IBD) increases bowel cancer risk: 1/3 of patients with low grade dysplasia (LGD) will get cancer. This risk is very high &reason for treatment. But also major conundrum b/c 2/3 patients with LGD won't get cancer. Can we know who is really at risk? 1/3

[Trevor Graham @trevoragraham]

Preprint is here: https://t.co/a7yw7qpmc1
Many years work by many amazing people (including): @IbrahimAlBakir1 @yosoykit @gcresswell @NadiaNasreddin @salpienowinski @DrAilsaHart @leedham_simon @BowelsOfStMarks @ICR_London [3/3]

[The Royal Family @RoyalFamily]

Thank you to all at @UCLH and @MacmillanCancer for your tireless work to provide cancer patients with the best care and support. 

Marking His Majesty’s return to public duties, The King and Queen spent time with patients to hear about their ongoing treatment and support.

[UCLH @uclh]

Today, King Charles III and Queen Camilla met patients and families living with #cancer to hear their hopes and fears as they received care at our cancer centre.

Thank you for taking the time to listen to our patients' experiences.

Read more: https://t.co/mNdGNVHViG

[David Probert @probert_david]

It was a great honour to welcome Their Majesties to @uclh today. A wonderful opportunity to meet some of our patients and spend time with our fabulous #OneTeam staff